How Ventavis Helps Patients with Pulmonary Arterial Hypertension Symptoms (NYHA Class III/IV)
How does Ventavis help treat PAH?
Ventavis is delivered right to the lungs—the site of the disease. Ventavis is the only inhaled PAH therapy that can be given alone to help patients treat PAH symptoms to walk farther and breathe easier with ordinary physical activities. It can also be safely used with many other drugs. Ventavis is approved for the treatment of NYHA Class III or IV pulmonary arterial hypertension (PAH).
In clinical studies, Ventavis has been shown to decrease pulmonary arterial hypertension signs including lowering high blood pressure and resistance in the pulmonary artery (main blood vessel) leading to the lungs to allow the heart to pump more efficiently.1 Ventavis is also the only inhaled therapy which has shown that patients have clinical improvement with treatment — defined as the combination of three different clinical measurements.
|
|
 |
 |
Patients were able to walk farther in a timed test.1
Patients who took Ventavis were able to walk farther by at least 10% in a 6- minute walk test. On average, patients who took Ventavis could walk 40 meters farther than those who did not take Ventavis.
|
 |
|
Ventavis decreased the worsening of PAH symptoms.1
PAH is a progressive disease, which means it tends to get worse if not treated. Patients who took Ventavis had less worsening of PAH symptoms.
Individual patient results may vary.
|
 |
Inhaled therapy for PAH
Because it is inhaled, Ventavis allows patients to avoid infections and other complications that may occur with pumps, needles, and catheters—the other ways to deliver man-made prostacyclin into the body.
Read about:
Who Takes Ventavis?
Ventavis Patient Stories
Safety Information
|
How Ventavis Helps
